News from alkermes plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

08 Jan, 2020, 21:00 GMT Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38th Annual J.P. Morgan Healthcare Conference ...


26 Nov, 2019, 21:01 GMT Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Evercore ISI...


25 Nov, 2019, 12:00 GMT Alkermes Completes Acquisition of Rodin Therapeutics

Alkermes plc (Nasdaq: ALKS) today announced that it has completed its previously announced acquisition of Rodin Therapeutics, Inc. (Rodin), a...


19 Nov, 2019, 12:00 GMT Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder

Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking ...


18 Nov, 2019, 12:00 GMT Alkermes to Acquire Rodin Therapeutics

Alkermes plc (Nasdaq: ALKS) and Rodin Therapeutics, Inc. (Rodin) today announced that they have entered into a definitive agreement under which...


12 Nov, 2019, 21:01 GMT Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Stifel 2019 Healthcare Conference on Tuesday, ...


12 Nov, 2019, 12:00 GMT Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™

Alkermes plc (Nasdaq: ALKS) today announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.S. Food and Drug...


08 Nov, 2019, 12:00 GMT Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

Alkermes plc (Nasdaq: ALKS) today presented new data from the company's ARTISTRY clinical development program related to ALKS 4230 at the Society for ...


04 Nov, 2019, 12:00 GMT Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced that it will present new data from its ARTISTRY clinical development program related to ALKS 4230, an...


30 Oct, 2019, 11:30 GMT Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™...


23 Oct, 2019, 12:00 BST Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring

Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2019 and the implementation of a restructuring plan following a ...


21 Oct, 2019, 12:00 BST Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230

Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center...


16 Oct, 2019, 21:01 BST Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, October 23, 2019, to...


07 Oct, 2019, 12:00 BST Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress

Alkermes plc (Nasdaq: ALKS) today announced the presentation of new health economics and outcomes research at the 32nd Annual Psych Congress (Psych...


26 Sep, 2019, 21:01 BST Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference ...


13 Sep, 2019, 12:00 BST Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.

Alkermes plc (Nasdaq: ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.D. and Frank Anders (Andy) Wilson, to ...


30 Jul, 2019, 12:30 BST Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis

Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized,...


29 Jul, 2019, 17:30 BST Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute

Alkermes plc (Nasdaq: ALKS) announced today that it has entered into a settlement and license agreement (the agreement) with Amneal Pharmaceuticals...


25 Jul, 2019, 12:00 BST Alkermes Plc Reports Second Quarter 2019 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2019. "Our second quarter results reflect the growth of...


18 Jul, 2019, 21:01 BST Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, July 25, 2019, to...


15 Jul, 2019, 12:00 BST Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder

Alkermes plc (Nasdaq: ALKS) today provided an update on its regulatory strategy for ALKS 3831 (olanzapine/samidorphan), the company's...


01 Jul, 2019, 12:00 BST Alkermes Demonstrates Commitment to Local Community for 11th Consecutive Year With Largest Volunteer Event in Company History

Alkermes plc (Nasdaq: ALKS) today announced that for the 11th consecutive year, employees took a day out of the office to roll up their sleeves and...


12 Jun, 2019, 12:00 BST Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

Alkermes plc (Nasdaq: ALKS) today announced the initiation of the monotherapy expansion stage of its ARTISTRY-1 clinical trial to evaluate the...


22 May, 2019, 12:00 BST Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its mental health portfolio at the American Society of Clinical...


14 May, 2019, 21:01 BST Alkermes to Present at the UBS Global Healthcare Conference

Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson, will participate in a fireside chat...